摘要
点评RAO等[1]以综述形式对新型抗雄激素(novel antiandrogens,NHA)和多聚(ADP-核糖)聚合酶[poly(ADP-ribose)polymerase,PARP]抑制剂(PARP inhibitor,PARPi)在前列腺癌领域探索的过去、现在和未来进行了论述。转移性去势抵抗性前列腺癌(metastatic castration-resistant prostate cancer,mCRPC)有高度分子异质性,单纯靶向雄激素受体(androgen-receptor,AR)通路的治疗终会出现耐药性[2]。
作者
盛锡楠
Sheng Xinan(Key Laboratory of Carcinogenesis and Translational Research,Ministry of Education,Department of Kidney Cancer and Melanoma,Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处
《泌尿外科杂志（电子版）》
2023年第3期10-17,共8页
Journal of Urology for Clinicians(Electronic Version)
关键词
合成致死
新型疗法
转移性前列腺癌
晚期前列腺癌
转移性去势抵抗性前列腺癌
Syonthetic lethality
Novel therapy
Metastatic prostate cancer
Advanced prostate cancer
Metastatic castration-resistant prostate cancer
